FAS and glioblastoma: Furthermore, in a phase II clinical trial, targeted inhibition of CD95 signaling by interfering with the CD95/CD95L interaction in relapsed glioblastoma patients reportedly reduced the invasiveness of glioma cells and prolonged patient survival [274,289].